Bart A. Ploeger

3.2k total citations
67 papers, 2.3k citations indexed

About

Bart A. Ploeger is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Bart A. Ploeger has authored 67 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 17 papers in Oncology and 15 papers in Pharmacology. Recurrent topics in Bart A. Ploeger's work include Pharmacogenetics and Drug Metabolism (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Hormonal Regulation and Hypertension (6 papers). Bart A. Ploeger is often cited by papers focused on Pharmacogenetics and Drug Metabolism (13 papers), Colorectal Cancer Treatments and Studies (10 papers) and Hormonal Regulation and Hypertension (6 papers). Bart A. Ploeger collaborates with scholars based in Netherlands, Germany and United States. Bart A. Ploeger's co-authors include Meindert Danhof, Elizabeth C. M. de Lange, Joost DeJongh, Teun M. Post, Jan Meulenbelt, Nicholas H. G. Holford, Jan Freijer, R.A. Voskuyl, Adriënne J.A.M. Sips and Tjeert T. Mensinga and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Bart A. Ploeger

65 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bart A. Ploeger Netherlands	26	630	498	364	284	274	67	2.3k
Vangelis G. Manolopoulos Greece	28	1.2k 1.9×	727 1.5×	299 0.8×	323 1.1×	226 0.8×	135	3.2k
Yoseph Caraco Israel	27	432 0.7×	946 1.9×	337 0.9×	233 0.8×	296 1.1×	102	2.3k
Ji‐Hong Shon South Korea	27	335 0.5×	833 1.7×	501 1.4×	286 1.0×	245 0.9×	60	1.9k
Bennett Ma United States	16	356 0.6×	616 1.2×	467 1.3×	186 0.7×	186 0.7×	38	1.6k
Bradley L. Urquhart Canada	26	933 1.5×	418 0.8×	731 2.0×	193 0.7×	397 1.4×	79	2.9k
Roberto Padrini Italy	27	402 0.6×	646 1.3×	447 1.2×	275 1.0×	176 0.6×	104	2.7k
Ophelia Yin United States	28	433 0.7×	441 0.9×	647 1.8×	170 0.6×	261 1.0×	94	2.3k
Pei Hu China	26	778 1.2×	392 0.8×	589 1.6×	251 0.9×	93 0.3×	222	2.6k
Thomas Kerbusch Netherlands	22	411 0.7×	359 0.7×	347 1.0×	84 0.3×	239 0.9×	47	1.9k
Liyan Miao China	25	547 0.9×	317 0.6×	229 0.6×	146 0.5×	127 0.5×	129	2.0k

Countries citing papers authored by Bart A. Ploeger

Since Specialization

Citations

This map shows the geographic impact of Bart A. Ploeger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart A. Ploeger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart A. Ploeger more than expected).

Fields of papers citing papers by Bart A. Ploeger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart A. Ploeger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart A. Ploeger. The network helps show where Bart A. Ploeger may publish in the future.

Co-authorship network of co-authors of Bart A. Ploeger

This figure shows the co-authorship network connecting the top 25 collaborators of Bart A. Ploeger. A scholar is included among the top collaborators of Bart A. Ploeger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart A. Ploeger. Bart A. Ploeger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ploeger, Bart A., Andrea Wagenfeld, Herbert Wiesinger, et al.. (2025). Zabedosertib, a novel interleukin-1 receptor-associated kinase-4 inhibitor, shows a favorable pharmacokinetic and safety profile across multiple phase 1 studies. Frontiers in Pharmacology. 16. 1521505–1521505.

Casanova, Michela, Francisco Bautista, Guy Makin, et al.. (2023). Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study. Clinical Cancer Research. 29(21). 4341–4351. 19 indexed citations

Ploeger, Bart A., et al.. (2021). Point-of-care testing in out-of-hospital cardiac arrest: a retrospective analysis of relevance and consequences. Scandinavian Journal of Trauma Resuscitation and Emergency Medicine. 29(1). 128–128. 11 indexed citations

Ploeger, Bart A., et al.. (2021). Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview. Clinical Pharmacokinetics. 61(1). 1–16. 4 indexed citations

Solms, Alexander, Henk‐Jan Drenth, Jordi Bruix, et al.. (2017). Exposure–response relationship of regorafenib efficacy in patients with hepatocellular carcinoma. European Journal of Pharmaceutical Sciences. 109. S149–S153. 18 indexed citations

Block, Michael S., Bart A. Ploeger, Joachim Grevel, et al.. (2016). Evaluation of exposure of regorafenib and its metabolites in cancer patients with renal impairment by modelling, simulation, and clinical study. Annals of Oncology. 27. vi538–vi538. 1 indexed citations

Hest, Reinier M. van, et al.. (2013). Pharmacokinetic–Pharmacodynamic Modeling of the Antihypertensive Effect of Eprosartan in Black and White Hypertensive Patients. Clinical Pharmacokinetics. 52(9). 793–803. 6 indexed citations

Ploeger, Bart A., et al.. (2012). Predicting human exposure of active drug after oral prodrug administration, using a joined in vitro/in silico–in vivo extrapolation and physiologically-based pharmacokinetic modeling approach. Journal of Pharmacological and Toxicological Methods. 67(3). 203–213. 14 indexed citations

Press, Rogier R., Bart A. Ploeger, Jan den Hartigh, et al.. (2010). Explaining variability in ciclosporin exposure in adult kidney transplant recipients. European Journal of Clinical Pharmacology. 66(6). 579–590. 28 indexed citations

10.

Danhof, Meindert, et al.. (2008). Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends in Pharmacological Sciences. 29(4). 186–191. 206 indexed citations

11.

Ploeger, Bart A., Jean Smeets, Henk‐Jan Drenth, et al.. (2008). Pharmacokinetic-Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex. Anesthesiology. 110(1). 95–105. 36 indexed citations

12.

Ploeger, Bart A., Carla F.M. Molthoff, Hugo W. A. M. de Jong, et al.. (2008). Changes in GABA_A receptor properties in amygdala kindled animals: In vivo studies using [¹¹C]flumazenil and positron emission tomography. Epilepsia. 50(1). 88–98. 34 indexed citations

13.

Winter, Willem de, Joost DeJongh, Teun M. Post, et al.. (2006). A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus. Journal of Pharmacokinetics and Pharmacodynamics. 33(3). 313–343. 112 indexed citations

14.

Freijer, Jan, Teun M. Post, Bart A. Ploeger, Joost DeJongh, & Meindert Danhof. (2006). Application of the Convection–Dispersion Equation to Modelling Oral Drug Absorption. Bulletin of Mathematical Biology. 69(1). 181–195. 5 indexed citations

15.

Ploeger, Bart A., Carla F.M. Molthoff, Ronald Boellaard, et al.. (2005). Population Pharmacokinetic Analysis for Simultaneous Determination of B max and K D In Vivo by Positron Emission Tomography. Molecular Imaging and Biology. 7(6). 411–421. 20 indexed citations

16.

Ploeger, Bart A.. (2004). PK/PD modelling of reversal of neuromuscular blockade by a chemically optimised cyclodextrin. Clinical Pharmacology & Therapeutics. 75(2). P80–P80. 1 indexed citations

17.

Ploeger, Bart A., et al.. (2001). A Population Physiologically Based Pharmacokinetic/Pharmacodynamic Model for the Inhibition of 11-β-Hydroxysteroid Dehydrogenase Activity by Glycyrrhetic Acid. Toxicology and Applied Pharmacology. 170(1). 46–55. 23 indexed citations

18.

Ploeger, Bart A., Tjeert T. Mensinga, Adriënne J.A.M. Sips, Jan Meulenbelt, & Joost DeJongh. (2000). A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling.. Pharmaceutical Research. 17(12). 1516–1525. 37 indexed citations

19.

Ploeger, Bart A., Jan Meulenbelt, & Joost DeJongh. (2000). Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling. Toxicology and Applied Pharmacology. 162(3). 177–188. 47 indexed citations

20.

DeJongh, Joost, et al.. (1999). Estimation of Systemic Toxicity of Acrylamide by Integration of in Vitro Toxicity Data with Kinetic Simulations. Toxicology and Applied Pharmacology. 158(3). 261–268. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact